ESMO2016 Cancer market commentary: Roche’s Tecentriq muscles into NSC... Roche's PD-L1 drug has generated impressive data in second line lung cancer
ESMO2016 Eye on ESMO: Day 2 - gamechangers take centre stage Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
Partner Content Partner Content VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution? The rapid advancement of immunotherapy in recent years has presented a number of challenges to pharmaceutical firms looking to monitor and measure efficacy in patients.
News Keenova eyes Xiaflex as first drug for plantar fibromatosis Keenova is hoping that its Xiaflex drug can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
